Data gathered: November 27
AI Stock Analysis - Verve Therapeutics (VERV)
Analysis generated July 7, 2024. Powered by Chat GPT.
Verve Therapeutics is a biotechnology company focused on developing transformative, single-course gene-editing therapies to treat cardiovascular diseases. The company's pipeline includes innovative treatments targeting specific genetic causes of these conditions, ideally modifying patients' DNA to confer lifelong therapeutic benefits from a single administration.
Stock Alerts - Verve Therapeutics (VERV)
 |
Verve Therapeutics | November 27 Price is up by 5.7% in the last 24h. |
|
Verve Therapeutics | November 25 Price is up by 7.4% in the last 24h. |
|
Verve Therapeutics | November 22 Price is up by 5.4% in the last 24h. |
|
Verve Therapeutics | November 20 Price is down by -5.1% in the last 24h. |
Alternative Data for Verve Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,677 | Sign up | Sign up | Sign up |
| Twitter Followers | 4,880 | Sign up | Sign up | Sign up |
| Twitter Mentions | 9 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 86 | Sign up | Sign up | Sign up |
| Linkedin Employees | 298 | Sign up | Sign up | Sign up |
About Verve Therapeutics
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
| Price | $5.78 |
| Target Price | Sign up |
| Volume | 527,750 |
| Market Cap | $448M |
| Year Range | $4.4 - $13.28 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
 |
Cantor Fitzgerald Brokers Raise Earnings Estimates for VERVNovember 15 - ETF Daily News |
 |
Canaccord Genuity Group Issues Positive Forecast for Verve Therapeutics (NASDAQ:VERV) Stock PriceNovember 10 - ETF Daily News |
|
Equities Analysts Offer Predictions for VERV FY2024 EarningsNovember 9 - ETF Daily News |
|
What is William Blair’s Estimate for VERV FY2024 Earnings?November 8 - ETF Daily News |
|
Verve Therapeutics (NASDAQ:VERV) Price Target Lowered to $17.00 at Royal Bank of CanadaNovember 8 - ETF Daily News |
 |
Verve Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 5 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 6.9M | 14M | -14M | -50M | -55M | -0.590 |
| Q2 '24 | 6.7M | 15M | -15M | -50M | -57M | -0.590 |
| Q1 '24 | 5.7M | 18M | -19M | -49M | -55M | -0.590 |
| Q4 '23 | 7.3M | 16M | -8.3M | -48M | -52M | -0.690 |
| Q3 '23 | 3.1M | 12M | -12M | -46M | -51M | -0.720 |
Insider Transactions View All
| Ashe Andrew D. filed to buy 342,509 shares at $6.3. May 15 '24 |
| Nickerson Joan filed to sell 8,659 shares at $8.2. April 3 '24 |
| Yeshwant Krishna filed to buy 1,800,000 shares at $10. December 5 '23 |
| Dorval Allison filed to sell 4,060 shares at $11.5. December 1 '23 |
| Bellinger Andrew filed to sell 6,629 shares at $23. December 2 '22 |
Similar companies
Read more about Verve Therapeutics (VERV) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Verve Therapeutics?
The Market Cap of Verve Therapeutics is $448M.
What is the current stock price of Verve Therapeutics?
Currently, the price of one share of Verve Therapeutics stock is $5.78.
How can I analyze the VERV stock price chart for investment decisions?
The VERV stock price chart above provides a comprehensive visual representation of Verve Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Verve Therapeutics shares. Our platform offers an up-to-date VERV stock price chart, along with technical data analysis and alternative data insights.
Does VERV offer dividends to its shareholders?
As of our latest update, Verve Therapeutics (VERV) does not offer dividends to its shareholders. Investors interested in Verve Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Verve Therapeutics?
Some of the similar stocks of Verve Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.